Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) — Cash Flow Quality Index

Latest as of December 2025: -0.07x

Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) has a Cash Flow Quality Index of -0.07x as of December 2025. Operating cash flow of $-314.86K is below net income of $4.33 Million, suggesting accrual-heavy earnings not yet converted to cash. Also explore Drugs Made In America Acquisition II Cor balance sheet assets for the complete picture of this company's asset base.

Cash Flow Quality Index

-0.07x
Operating CF / Net Income

Operating Cash Flow

$-314.86K
USD

Net Income

$4.33 Million
USD

Data as of

Dec 2025
Most recent filing

Drugs Made In America Acquisition II Corp. Ordinary Shares Cash Flow Quality Index (2025–2025)

Historical Cash Flow Quality Index for Drugs Made In America Acquisition II Corp. Ordinary Shares across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Drugs Made In America Acquisition II Cor tangible book value ratio to evaluate the tangible quality of the company's equity base.

Annual Cash Flow Quality Index for Drugs Made In America Acquisition II Corp. Ordinary Shares (2025–2025)

Year-by-year earnings quality comparison for Drugs Made In America Acquisition II Corp. Ordinary Shares. For live market cap and the full company financial profile, see Drugs Made In America Acquisition II Cor market capitalisation.

Year Quality Index Operating CF (USD) Net Income YoY Change
2025 -0.24x $-1.02 Million $4.19 Million
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.